'Never been more urgent:' Scynexis looks to tackle superbug crisis with late-stage readout for antifungal hopeful
As the superbug crisis heats up around the world, Scynexis says it has new data from two interim analyses that prove its antifungal has the potential to treat a broad range of infections.
“The need for new anti-infectives capable of fighting the most resistant pathogens has never been more urgent as we confront the ongoing COVID-19 global pandemic,” CEO Marco Taglietti said in a statement.
The interim results come from two open-label Phase III trials for oral ibrexafungerp, dubbed FURI and CARES. In the FURI trial, the triterpenoid was given to patients with difficult-to-treat mucocutaneous and invasive fungal infections that are resistant to or intolerant of current standards of care, or who require a non-azole oral step-down therapy for the treatment of azole-resistant species. In the latest efficacy analysis, a data review committee observed “clinical benefit” in 30 of the 33 patients in a third cohort of patients, and no disease progression, according to Scynexis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
